Biocon - Global Healthcare Company
 
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > PRODUCTS & SERVICES
  Overview
  Biopharmaceuticals
  Licensing
  Contract Manufacturing
  Research Services
   
   Home
   
     
 

Biopharmaceuticals

Branded Formulations

- Oncology

  <<Back
 

  [MP] - Medical Professional
 

 

Nufil SF

Composition:

Recombinant Human-Granulocyte Colony Stimulating Factor (GCSF); filgrastim 300 µg

Available as a pre-filled syringe

Mechanism of Action:
Filgrastim (produced in E. coli) is a non-glycosylated recombinant G-CSF used to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. It also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.

Indications:
Cancer patients receiving myelosuppressive chemotherapy; patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; cancer patients receiving bone-marrow transplant (BMT); patients with severe chronic neutropenia; peripheral blood progenitor cell (PBPC) collection and therapy in cancer patients

Contraindications:
NUFIL SF™ is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Filgrastim, or any component of the product.




    Top
  Related links:
    Custom Research - Syngene
    Clinical Research - Clinigene
    Strategic Alliances
    Contact Us
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Clinigene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer | Authorised Users               © 2014, Biocon. All Rights Reserved